Overall, the pCR rate was 15% (n = 16/107), with a pCR of 3% for HR positive, HER2−; 33% for HER2+ breast cancers; and 30% for triple-negative breast cancers (TNBC) (Additional file 4: Table S3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.